Effects of Glucagon-Like Peptide-1 Receptor Agonists (Mono and Combination Therapy) on Energy Expenditure: A Scoping Review - PubMed
8 hours ago
- #GLP-1 receptor agonists
- #energy expenditure
- #obesity management
- GLP-1 receptor agonists (GLP-1RA) are used for obesity management, but their effects on energy expenditure (EE) are unclear.
- A scoping review analyzed 23 studies on GLP-1RA (mono and combination therapy) and its impact on EE.
- Most studies assessed resting metabolic rate (RMR), with few using 24-h indirect calorimetry and none using doubly labeled water.
- 34.8% of studies found GLP-1RA therapy had non-significant effects on EE.
- Combination therapy with glucagon or GIP showed varied impacts on EE components, such as RQ and fat utilization.
- 47.8% of studies had inconclusive results due to statistical limitations.
- GLP-1RA monotherapy does not appear to affect EE independently of weight loss.
- Combination therapies may influence EE differently, warranting further research.